Venetoclax (Venclyxto®) in combination with rituximab is indicated for the treatment of adult patients with CLL who have received at least one prior therapy.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||26/09/2018|
|Rapid review completed||18/10/2018|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of venetoclax compared with the current standard of care.|